<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587482</url>
  </required_header>
  <id_info>
    <org_study_id>PROG/11/79</org_study_id>
    <nct_id>NCT01587482</nct_id>
  </id_info>
  <brief_title>PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis</brief_title>
  <acronym>PLAISIR</acronym>
  <official_title>PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nowadays, stenting is became a standard of care in revascularization for superficial femoral&#xD;
      artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains&#xD;
      in-stent restenosis (ISR). While most of local therapies have failed to demonstrate&#xD;
      significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous&#xD;
      transluminal angioplasty remains the current standard of care for this indication. Recent&#xD;
      studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo&#xD;
      lesions and of coronary ISR. FREERIDE, a French prospective cohort has been set up to&#xD;
      evaluate the safety and the efficacy of drug eluting balloon (DEB) for the treatment of SFA&#xD;
      atherosclerotic lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>at 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events through</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target extremity revascularization (TER)</measure>
    <time_frame>at 1, 3, 6, 9, 12 and 18 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical improvement equal or above to a stage according to Rutherford classification without superficial femoral artery revascularization</measure>
    <time_frame>at 1, 3, 6, 9, 12 and 18 months</time_frame>
    <description>to assess primary maintenance of clinical improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak systolic velocity index without Target Lesion Revascularization</measure>
    <time_frame>at 1, 3, 6, 9, 12 and 18 months</time_frame>
    <description>to assess primary patency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment by EQ5D questionnaire</measure>
    <time_frame>at 1, 3, 6, 9, 12 and 18 mois after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-angioplasty restenosis</measure>
    <time_frame>at 1, 3, 6, 9, 12 and18 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drug relief success without balloon break</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization stay</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical improvement equal or above to a stage according to Rutherford classification with possible superficial femoral artery surgery</measure>
    <time_frame>at 1, 3, 6, 9, 12 and 18 months</time_frame>
    <description>to assess secondary maintenance of clinical improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak systolic velocity index</measure>
    <time_frame>at 1 year</time_frame>
    <description>to assess secondary patency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra-stent restenosis</measure>
    <time_frame>at 1, 3, 6, 9, 12 and 18 months after surgery</time_frame>
    <description>significant whether restenosis &gt;50% and peak systolic velocity index &gt; 2.4</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">53</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>drug eluting balloon</arm_group_label>
    <description>In this observationnal study, the intervention of interest is the use of drug eluting balloon in stent restenosis.&#xD;
Only the treated patients were included in this cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PacLitaxel Eluting Balloon Application</intervention_name>
    <description>Stenting is a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR). While most of local therapies have failed to demonstrate significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous transluminal angioplasty remains the current standard of care for this indication. Recent studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo lesions and of coronary ISR.</description>
    <arm_group_label>drug eluting balloon</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        From December 2011 to December 2012 at 13 hospitals in France, we will include patients&#xD;
        with symptomatic atherosclerotic lesions related to superficial femoral artery in-stent&#xD;
        restenosis to undergo endovascular repair by paclitaxel drug eluting balloon. 100 patients&#xD;
        will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
          -  Symptomatic patient according to Rutherford Class 1, 2, 3, 4 or 5&#xD;
&#xD;
          -  Clinical degradation by at least 1 Rutherford stage or absence of healing of all skin&#xD;
             lesions&#xD;
&#xD;
          -  Symptoms related to SFA ISR defined by PSVR &gt; 2.4 within 3 to 24 months after SFA&#xD;
             stenting of de novo atherosclerotic lesions. Each patient may have either one or both&#xD;
             limbs treated in the study&#xD;
&#xD;
          -  The target ISR lesion is fully comprised between the origin of the SFA and distally&#xD;
             the femoropopliteal crossover (crossing by SFA of medial rim of femur in the PA&#xD;
             projection)&#xD;
&#xD;
          -  Adequate SFA inflow and outflow either pre-existing or successfully re-established&#xD;
             (outflow defined as patency of at least one infragenicular artery)&#xD;
&#xD;
          -  The target lesion must no extend beyond the stent margin&#xD;
&#xD;
          -  Successful crossing of the target lesion, inflow and outflow lesions with a guidewire&#xD;
&#xD;
          -  Patient belongs to the French health care system&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No atheromatous disease&#xD;
&#xD;
          -  Asymptomatic lesion&#xD;
&#xD;
          -  Known allergies to heparin, aspirin, other anti-coagulant/antiplatelet therapies,&#xD;
             and/or paclitaxel&#xD;
&#xD;
          -  Acute limb ischemia&#xD;
&#xD;
          -  Patient on oral anticoagulation therapy&#xD;
&#xD;
          -  Target lesion requires / has been pre-treated with alternative therapy such as: DES,&#xD;
             laser, atherectomy, cryoplasty, cutting/scoring balloon, etc.&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
&#xD;
          -  Patient involved in another trial&#xD;
&#xD;
          -  Refusing patient&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Reix, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amiens's Univeristy Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Ducasse, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pellegrin's University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Lermusiaux, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lyon's University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marc Pernes, Practitioner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antony's private Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Louis, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Le Raincy-Montfermeuil Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine Sauget, Practitioner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pasteur's private Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Commeau, Practitioner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ollioules private Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Noel Albertini, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Etienne University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier Planché, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Le Plessis-Robinson private hospital (CMC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Max Amor, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Essey-les-Nancy Private hospital (Polyclinique Pasteur)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marie Cardon, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nimes private Hospital (clinique des fransiscaines)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain Cardon, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>April 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superficial femoral artery</keyword>
  <keyword>endovascular</keyword>
  <keyword>Drug eluting balloon</keyword>
  <keyword>Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

